Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BELLUS Health Inc BLUSD


Primary Symbol: T.BLU

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


TSX:BLU - Post by User

Bullboard Posts
Post by webpiloton Jan 17, 2011 10:06am
348 Views
Post# 17982984

Share Outstanding

Share OutstandingThe amount of shares outstanding right now or in the future doesn't really  matter right now.  What matters is will NRM8499 be successful.  Also will the company be able to finance it on its own.  This is a disease modifying solution for Alzheimer's, it is not an attempt to treat the symptoms.  At the present time there is absolutely nothing that is effective for Alzheimer's even the approved prescription drugs authorized by the FDA do not work.  If you don't believe me just go to the National Institutes of Health website and see for yourself.

Some comments on costs associated with Alzheimer's:

The global care cost for people with Alzheimer's disease and other forms of dementia is estimated at US$601 billion for the year 2010, which is more than 1percent of the global GDP in the same year, according to a report released Tuesday.

The report by the Alzheimer's Disease International (ADI) says the care for an estimated 35.6 million people with Alzheimer's disease and other dementias,when viewed as a country, would be the world's 18th largest economy somewhere between Turkey and Indonesia; when viewed as a company, the cost would be more than the annual revenue of Wal-Mart ($414 billion) and Exxon Mobil ($311billion).

The Chicago-based Alzheimer’s Association also released a 2010 report saying that the care cost for 5.3 million Americans with Alzheimer's disease is $172billion a year. Per capita, the cost for each person with the disease is $32,453 annually.

Although the United States pays a high price for the care given patients with Alzheimer's disease, the Alzheimer's disease mortality is on the rise.The AA report says that Alzheimer's deaths increased 46.1 percent from2000 to 2006.

So, you can see if BLU is successful, the payoff will be so huge that it is impossible to calculate.  It will be necessary to have a large float just to keep the price under control.  The stock price will rise to unimaginable heights.

Also, Kiacta on its own will yield a great stock price, and don't forget to add in Vivimind.  So if the outstanding float bothers you, it is not a good reason to bypass this tremendous opportunity.

Remember, it is impossible to calculate the future value and stock price if the company is successful with NRM8499.


Bullboard Posts